E6011 + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Biliary Cholangitis
Conditions
Primary Biliary Cholangitis
Trial Timeline
May 29, 2017 → Oct 22, 2018
NCT ID
NCT03092765About E6011 + Placebo
E6011 + Placebo is a phase 2 stage product being developed by Eisai for Primary Biliary Cholangitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03092765. Target conditions include Primary Biliary Cholangitis.
What happened to similar drugs?
20 of 20 similar drugs in Primary Biliary Cholangitis were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03733314 | Phase 2 | Completed |
| NCT03092765 | Phase 2 | Terminated |
| NCT02960490 | Phase 2 | Completed |
| NCT02960438 | Phase 2 | Completed |
| NCT02249078 | Phase 1 | Withdrawn |
| NCT02146261 | Phase 1 | Completed |
Competing Products
20 competing products in Primary Biliary Cholangitis